Latest newsClick here to be added to our mailing list
- Nicox to acquire 100% of Eupharmed for €3.5 million in newly issued Nicox shares, plus potential additional earn-out payment
- Acquisition of Eupharmed brings Nicox a direct marketing presence in Italy, an established product portfolio and sales platform for the launch of new products, including AdenoPlus®
- Sales from Eupharmed’s extensive ophthalmic portfolio including pharmaceuticals, medical devices and nutraceuticals totalled €3.6 million in 2012
- Italy’s ophthalmic market is one of the largest in Europe, with annual sales of more than €430 million1
Nicox launches Sjö™, an advanced diagnostic for early detection of Sjögren’s Syndrome, a serious, progressive and underdiagnosed autoimmune disease; US eye care professionals are uniquely positioned to identify Sjögren’s Syndrome as dry eye is a common early symptom.